Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
1999 4
2000 7
2001 8
2002 9
2003 18
2004 27
2005 42
2006 51
2007 102
2008 109
2009 155
2010 175
2011 175
2012 203
2013 224
2014 232
2015 232
2016 241
2017 215
2018 203
2019 169
2020 171
2021 199
2022 144
2023 134
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

2,905 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Two patients randomly assigned to mogamulizumab withdrew consent before receiving study treatment; thus, 370 patients were included in the safety population. ...Grade 3-4 adverse events of any cause were reported in 75 (41%) of 184 patients in the moga …
Two patients randomly assigned to mogamulizumab withdrew consent before receiving study treatment; thus, 370 patients w …
Increased recombinant adeno-associated virus production by HEK293 cells using small molecule chemical additives.
Scarrott JM, Johari YB, Pohle TH, Liu P, Mayer A, James DC. Scarrott JM, et al. Biotechnol J. 2023 Mar;18(3):e2200450. doi: 10.1002/biot.202200450. Epub 2022 Dec 22. Biotechnol J. 2023. PMID: 36495042 Free article.
Genome titre improvement was found to be scalable and serotype independent across two distinct rAAV serotypes, rAAV8 and rAAV9. Furthermore, a combination of M344 and nocodazole produced a positive additive effect on rAAV8 genome titre, resulting in a three-fold increase i …
Genome titre improvement was found to be scalable and serotype independent across two distinct rAAV serotypes, rAAV8 and rAAV9. Furthermore, …
A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma.
Ramos L, Truong S, Zhai B, Joshi J, Ghaidi F, Lizardo MM, Shyp T, Kung SHY, Rezakhanlou AM, Oo HZ, Adomat H, Le Bihan S, Collins C, Bacha J, Brown D, Langlands J, Shen W, Lallous N, Sorensen PH, Daugaard M. Ramos L, et al. Clin Cancer Res. 2023 Sep 1;29(17):3541-3553. doi: 10.1158/1078-0432.CCR-22-3897. Clin Cancer Res. 2023. PMID: 37279093 Free PMC article.
RESULTS: Compared with FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewing sarcoma models. ...In three-dimensional spheroid models of Ewing sarcoma, kt-3283 showed efficacy in lower concentrations than olaparib an …
RESULTS: Compared with FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewin …
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Zain J, Rosen S, Forman S, Popplewell L, Kwak L, Herrera AF. Mei M, et al. Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485. Blood. 2023. PMID: 37339586
This phase 1 study evaluated the addition of vorinostat to pembrolizumab in patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma, and follicular lymphoma. ...Vorinostat 100 mg twice a day (DL1) and 200 …
This phase 1 study evaluated the addition of vorinostat to pembrolizumab in patients with relapsed/refractory (RR) clas …
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer.
Wu Y, Chen S, Shao Y, Su Y, Li Q, Wu J, Zhu J, Wen H, Huang Y, Zheng Z, Chen X, Ju X, Huang S, Wu X, Hu Z. Wu Y, et al. Adv Sci (Weinh). 2023 Nov;10(31):e2304638. doi: 10.1002/advs.202304638. Epub 2023 Sep 13. Adv Sci (Weinh). 2023. PMID: 37702443 Free PMC article.
Here, super-enhancer (SE) regulatory elements that are aberrantly activated in OC are identified and it is found that SEs drive the relative specific expression of the transcription factor KLF5 in OC patients and poly(ADP-ribose) polymerase inhibitor (PARPi)-resistant p …
Here, super-enhancer (SE) regulatory elements that are aberrantly activated in OC are identified and it is found that SEs drive the relative …
Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer.
Lian B, Chen X, Shen K. Lian B, et al. Front Immunol. 2023 Mar 9;14:1164514. doi: 10.3389/fimmu.2023.1164514. eCollection 2023. Front Immunol. 2023. PMID: 36969235 Free PMC article. Review.
In recent years, immunotherapy has potentiated the survival of certain breast cancer patients; however, primary resistance or acquired resistance attenuate the therapeutic outcomes. ...HDAC inhibitors ameliorated immunotherapeutic efficacy in cancer patients. In thi …
In recent years, immunotherapy has potentiated the survival of certain breast cancer patients; however, primary resistance or acquire …
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Dimopoulos M, et al. Lancet Oncol. 2013 Oct;14(11):1129-1140. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19. Lancet Oncol. 2013. PMID: 24055414 Clinical Trial.
BACKGROUND: We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or refractory multiple myeloma. METHODS: In our randomised, double-blind, …
BACKGROUND: We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of …
Vorinostat as potential antiparasitic drug.
Herrera-Martínez M, Orozco-Samperio E, Montaño S, Ariza-Ortega JA, Flores-García Y, López-Contreras L. Herrera-Martínez M, et al. Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7412-7419. doi: 10.26355/eurrev_202007_21909. Eur Rev Med Pharmacol Sci. 2020. PMID: 32706080 Free article. Review.
OBJECTIVE: Vorinostat is a drug used to treat cutaneous T cell lymphoma whose action mechanism is based on Histone Deacetylase inhibition. ...CONCLUSIONS: In vitro and in vivo models have demonstrated the antiparasitic activity of Vorinostat, however, the challenge …
OBJECTIVE: Vorinostat is a drug used to treat cutaneous T cell lymphoma whose action mechanism is based on Histone Deacetylase inhibi …
Vorinostat decrease M2 macrophage polarization through ARID1A(6488delG)/HDAC6/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma.
Hsieh TH, Hsu CY, Wu CW, Wang SH, Yeh CH, Cheng KH, Tsai EM. Hsieh TH, et al. Biomed Pharmacother. 2023 May;161:114500. doi: 10.1016/j.biopha.2023.114500. Epub 2023 Mar 21. Biomed Pharmacother. 2023. PMID: 36958195 Free article.
We also found that ARID1A(6488delG)/HDAC6 induced M2 polarization of macrophages through IL-10. In addition, the HDAC inhibitor (HDACi) vorinostat inhibited cell growth and blocked the effect of HDAC6. Tomographic microscopy was used to monitor the live cell morphology of …
We also found that ARID1A(6488delG)/HDAC6 induced M2 polarization of macrophages through IL-10. In addition, the HDAC inhibitor (HDACi) v …
Maintenance therapy in multiple myeloma: Two is not always better than one.
Offidani M, Morè S, Corvatta L. Offidani M, et al. Br J Haematol. 2023 Apr;201(2):181-182. doi: 10.1111/bjh.18614. Epub 2022 Dec 21. Br J Haematol. 2023. PMID: 36541138 Clinical Trial.
In multiple myeloma (MM) long-term therapy aims to control disease and delay progression for as long as possible. ...Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple …
In multiple myeloma (MM) long-term therapy aims to control disease and delay progression for as long as possible. ...Commentar …
2,905 results